03月 26日, 2019
Dr. Liang-Gee Chen, Minister of Ministry of Science and Technology (MOST), announced the 10 coolest tech startup companies today at Taiwan Tech Arena (TTA). The Taiwan government has invested the resources in building a tech startup ecosystem in Taiwan, this policy has encouraged many startups come up with innovative ideas and solution to emerged into the market. This year, the Ministry of Scie...
12月 25日, 2018
APRINOIA Therapeutics, a clinical-stage biotechnology company developing therapeutics and diagnostic imaging tools for neurodegenerative diseases, announced today that it has entered into a non-exclusive licensing agreement with Celgene Corporation. The agreement authorizes Celgene to use APN-1607, a novel investigational [ F]-labeled positron emission tomography (PET) imaging tracer, to suppo...
09月 01日, 2018
APRINOIA Will Participate Asia-China: 2018 Clinical Trials on Alzheimer’s Disease Conference
APRINOIA will sponsor the first Clinical Trials on Alzheimer's Disease Conference (CTAD) in Asia. The conference will take place in Shanghai on September 1st and 2nd. APRINOIA will be presenting the latest clinical data of our lead tau PET Imaging tracer, APN-1607 (PM-PBB3), and the current progress of our therapeutics programs at the conference.
01月 16日, 2018
APRINOIA Therapeutics Inc., a clinical-stage neuroscience biotech company, focuses on tau, alpha-synuclein, and novel targets for neurodegenerative diseases, announces today the completion of its US$11.1 million Series B round. The Series B round was led by KTB Network (Korea) and DCI Partners (Japan), along with participations from ShangPharma Investment Group (China) and TaiAn Technologies (T...
12月 15日, 2017
APRNIOIA Will participate 2018 Human Amyloid Imaging Conference
APRINOIA will present the latest result for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the Human Amyloid Imaging (HAI) Conference in Miami in January 2018.
12月 15日, 2017
APRNIOIA Will Participate 2018 AAT-AD/PD Focus Meeting
APRINOIA will present the latest result for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) and its tau therapeutic program at the 2018 AAT-AD/PD Focus Meeting in Torino in March 2018.
12月 15日, 2017
APN-1607 (PM-PBB3) Receives US FDA Orphan Drug Designation
APRINOIA's lead tau PET imaging tracer, APN-1607 (PM-PBB3), has received US FDA Orphan Drug Designation.
12月 12日, 2016
APRINOIA Will Present its 1st Clinical Trial Results at 2017 Human Amyloid Imaging Conference
APRINOIA will present the first-in-the-human clinical trial results for its Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the Human Amyloid Imaging (HAI) Conference in Miami in January 2017.